Evidence map›Paper›PMID 38174103›Full record

ArticleNew microbes and new infections2024

Long COVID-associated symptoms prevalent in both SARS-CoV-2 positive and negative individuals: A prospective follow-up study.

Anu Kantele, Juuso Paajanen, Jukka-Pekka Pietilä, Olli Vapalahti, Sari H Pakkanen, Tinja Lääveri

Open access · goldAbstract read
In one paragraph

Article in New microbes and new infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Anu KanteleMeilahti Infectious Diseases and Vaccine Research Center, MeiVac, Biomedicum 1, Haartmaninkatu 8, Helsinki University Hospital and University of Helsinki, 00290, Helsinki, Finland.
Juuso PaajanenDepartment of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland.
Jukka-Pekka PietiläMeilahti Infectious Diseases and Vaccine Research Center, MeiVac, Biomedicum 1, Haartmaninkatu 8, Helsinki University Hospital and University of Helsinki, 00290, Helsinki, Finland.
Olli VapalahtiViral Zoonoses Research Unit, Departments of Virology and Veterinary Biosciences, Faculties of Medicine and Veterinary Medicine, 00014, University of Helsinki, Helsinki, Finland.
Sari H PakkanenMeilahti Infectious Diseases and Vaccine Research Center, MeiVac, Biomedicum 1, Haartmaninkatu 8, Helsinki University Hospital and University of Helsinki, 00290, Helsinki, Finland.
Tinja LääveriMeilahti Infectious Diseases and Vaccine Research Center, MeiVac, Biomedicum 1, Haartmaninkatu 8, Helsinki University Hospital and University of Helsinki, 00290, Helsinki, Finland.
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Research into persistent symptoms among SARS-CoV-2-positive i.e. CoV(+) patients mostly focuses on hospitalized individuals. Our prospective follow-up study compares long COVID-associated symptoms among laboratory-confirmed CoV(+) and SARS-CoV-2 negative [CoV(-)] individuals. Methods: SARS-CoV-2 RT-PCR-tested volunteers were recruited into four cohorts: 1) CoV(+) outpatients, 2) CoV(-) outpatients, 3) CoV(+) intensive care unit (ICU) inpatients, and 4) CoV(+) non-ICU inpatients. Neutralizing antibodies were assessed and questionnaires filled in at enrolment and days 90-120, 121-180, 181-270, 271-365, and 365-533. Results: Of the 1326 participants, 1191 were CoV(+): 46 ICU, 123 non-ICU, and 1022 outpatients; 135 were CoV(-) outpatient controls. Both CoV(+) outpatients and CoV(-) controls showed high overall symptom rates at all time points. More prevalent among CoV(+) than CoV(-) outpatients were only impaired olfaction and taste; many others proved more frequent for CoV(-) participants. At ≥181 days, fatigue, dyspnoea, various neuropsychological symptoms and several others were recorded more often for CoV(+) inpatients than outpatients. Conclusions: Long COVID-associated symptoms were more frequent among hospitalized than non-hospitalized CoV(+) participants. As for outpatients, only impaired olfaction and taste showed higher rates in the CoV(+) group; some symptoms proved even more common among those CoV(-). Besides suggesting low long COVID prevalences for outpatients, our results highlight the weight of negative controls.

Indexed as

Follow-up studyLong covidSARS-CoV-2

Identifiers

PMID38174103
PMCPMC10761764
OpenAlexW4389455093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.